Cargando…

Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer

Background: The role of neoadjuvant chemotherapy (NAC) in the prognosis of breast cancer among patients with grade 2 tumors remains unclear. As such, we aimed to explore the relationships between NAC and survival outcomes among patients with grade 2 breast cancer. Materials and Methods: We collected...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xudong, Xue, Jinqi, Gu, Xi, Chen, Guanglei, Cao, Fangning, Shan, Huilian, Wang, Dan, Qiao, Xinbo, Liu, Caigang, Zhang, Yixiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843887/
https://www.ncbi.nlm.nih.gov/pubmed/31737103
http://dx.doi.org/10.7150/jca.33168
_version_ 1783468321782366208
author Zhu, Xudong
Xue, Jinqi
Gu, Xi
Chen, Guanglei
Cao, Fangning
Shan, Huilian
Wang, Dan
Qiao, Xinbo
Liu, Caigang
Zhang, Yixiao
author_facet Zhu, Xudong
Xue, Jinqi
Gu, Xi
Chen, Guanglei
Cao, Fangning
Shan, Huilian
Wang, Dan
Qiao, Xinbo
Liu, Caigang
Zhang, Yixiao
author_sort Zhu, Xudong
collection PubMed
description Background: The role of neoadjuvant chemotherapy (NAC) in the prognosis of breast cancer among patients with grade 2 tumors remains unclear. As such, we aimed to explore the relationships between NAC and survival outcomes among patients with grade 2 breast cancer. Materials and Methods: We collected data on 726 breast cancer patients with grade 2 tumors and at least 5-years of follow-up from the date of diagnosis. We then conducted survival analyses to examine the association between NAC and disease-free survival (DFS) and overall survival (OS). The role of NAC in prognosis was further examined in subgroup analyses, with patients stratified according to molecular subtypes, histological grade, ER status, PR status, HER2 status and Ki67 index. We also determined the main sites of local recurrence, as well as these organs involved in distant metastasis among patients receiving NAC. Finally, we analyzed independent predictive factors for DFS and OS using Cox regression analyses. Results: Among patients who received NAC, the prevalence of pathologic complete response (pCR) was 9.87% (23/233), with 32.6% of patients (76/233) experiencing partial response. Survival analyses demonstrated that NAC had an overall adverse effect on DFS and OS. Subgroup analyses showed that patients who received NAC had shorter DFS in all molecular subgroups of breast cancer, with exception of triple negative breast cancer (TNBC) patients. NAC was also associated with shorter OS among patients with histological grade of 2 and a low Ki67 index. The main recurrence site was the chest well, while distant metastasis occurred in the bone, liver and lung. In Cox regression analyses, we found that NAC was an independent predictor for DFS, but not for OS. Conclusions: NAC may have an adverse effect on breast cancer prognosis among patients with grade 2 tumors. These patients need not receive NAC, except when the patient has a strong desire for breast conservation, and this is unlikely to be achieved in the absence of NAC.
format Online
Article
Text
id pubmed-6843887
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-68438872019-11-15 Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer Zhu, Xudong Xue, Jinqi Gu, Xi Chen, Guanglei Cao, Fangning Shan, Huilian Wang, Dan Qiao, Xinbo Liu, Caigang Zhang, Yixiao J Cancer Research Paper Background: The role of neoadjuvant chemotherapy (NAC) in the prognosis of breast cancer among patients with grade 2 tumors remains unclear. As such, we aimed to explore the relationships between NAC and survival outcomes among patients with grade 2 breast cancer. Materials and Methods: We collected data on 726 breast cancer patients with grade 2 tumors and at least 5-years of follow-up from the date of diagnosis. We then conducted survival analyses to examine the association between NAC and disease-free survival (DFS) and overall survival (OS). The role of NAC in prognosis was further examined in subgroup analyses, with patients stratified according to molecular subtypes, histological grade, ER status, PR status, HER2 status and Ki67 index. We also determined the main sites of local recurrence, as well as these organs involved in distant metastasis among patients receiving NAC. Finally, we analyzed independent predictive factors for DFS and OS using Cox regression analyses. Results: Among patients who received NAC, the prevalence of pathologic complete response (pCR) was 9.87% (23/233), with 32.6% of patients (76/233) experiencing partial response. Survival analyses demonstrated that NAC had an overall adverse effect on DFS and OS. Subgroup analyses showed that patients who received NAC had shorter DFS in all molecular subgroups of breast cancer, with exception of triple negative breast cancer (TNBC) patients. NAC was also associated with shorter OS among patients with histological grade of 2 and a low Ki67 index. The main recurrence site was the chest well, while distant metastasis occurred in the bone, liver and lung. In Cox regression analyses, we found that NAC was an independent predictor for DFS, but not for OS. Conclusions: NAC may have an adverse effect on breast cancer prognosis among patients with grade 2 tumors. These patients need not receive NAC, except when the patient has a strong desire for breast conservation, and this is unlikely to be achieved in the absence of NAC. Ivyspring International Publisher 2019-09-07 /pmc/articles/PMC6843887/ /pubmed/31737103 http://dx.doi.org/10.7150/jca.33168 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Zhu, Xudong
Xue, Jinqi
Gu, Xi
Chen, Guanglei
Cao, Fangning
Shan, Huilian
Wang, Dan
Qiao, Xinbo
Liu, Caigang
Zhang, Yixiao
Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer
title Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer
title_full Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer
title_fullStr Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer
title_full_unstemmed Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer
title_short Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer
title_sort neoadjuvant chemotherapy plays an adverse role in the prognosis of grade 2 breast cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843887/
https://www.ncbi.nlm.nih.gov/pubmed/31737103
http://dx.doi.org/10.7150/jca.33168
work_keys_str_mv AT zhuxudong neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer
AT xuejinqi neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer
AT guxi neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer
AT chenguanglei neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer
AT caofangning neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer
AT shanhuilian neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer
AT wangdan neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer
AT qiaoxinbo neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer
AT liucaigang neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer
AT zhangyixiao neoadjuvantchemotherapyplaysanadverseroleintheprognosisofgrade2breastcancer